Abstract: Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-imidazolyl)-ami no]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Abstract: Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-immidazolyl)-am ino]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of substituted benzamides of formula (1): ##STR1## in which: A is linear or branched C.sub.1 -C.sub.3 alkyl; allyl or diethylaminoethyl;R.sub.1 is hydrogen or methyl, andZ-- is --NH--, --O-- or --S--,and of their pharmacologically acceptable salts for modifying gastric motility.

Abstract: The present invention relates to the application of substituted benzamides of formula (I): ##STR1## in which: A is diethylaminoethyl, 1-ethyl-2-pyrrolidinylmethyl or 1-allyl-2-pyrrolidinylmethyl;R.sub.1 is hydrogen or methyl;X is chlorine or bromine;Z is --NH-- or --O-- except when Z is --NH--,R.sub.1 is hydrogen and X is chlorine, and of their pharmacologically acceptable addition salts, as anxiolytics and antipsychotics.

Abstract: The invention relates to new dihydrobenzofuran- and chroman-carboxamide derivatives of the general formula: ##STR1## in which R and R' are each hydrogen or methyl; n is 1 or 2; m is 1 or 2; Z is either ##STR2## wherein R.sub.1 and R.sub.2 are lower alkyl, or ##STR3## wherein R.sub.3 is alkyl, alkenyl, cycloalkyl-alkyl, cycloalkenyl-alkyl, X is H, NH.sub.2, methoxy, or methyl and Y is H, Cl, cycloalkylmethylsulfonyl, alkylsulfamoyl or alkylsulfonyland to their pharmacologically acceptable acid addition salts and their optical isomers, to the processes for the preparation thereof and to the use thereof as medicaments, especially as neuroleptics.